A meta-analysis illustrated good effectiveness and safety of atogepant (10 mg, 30 mg, 60 mg once a day) for the prophylactic therapy of migraine. Xinyu Tao et al. aimed to determine atogepant's safety and efficacy to treat migraine. For finding out relevant studies, databases such as ClinicalTrials.gov, Embase, MEDLINE and Cochrane Library were searched.

Overall, three randomized clinical trials (RCTs) with 2,466 participants were incorporated in this meta-analysis. Mean monthly migraine days was the major outcome ascertained while acute medication use days per month, monthly headache days, and ≥ 50% drop in monthly migraine days from baseline to the end of trials were the secondary outcomes ascertained.

With atogepant use, a substantial drop in the monthly headache and migraine days, and monthly medication use days was noted. Further, there was a rise in the percentage of individuals with ≥ 50% decrease in monthly migraine days when compared to placebo. Furthermore, no profound differences were witnessed in the outcomes of adverse events between placebo and atogepant groups. Thus, atogepant (calcitonin gene-related peptide receptor antagonist) is valuable for migraine attacks prevention.